STEREOTAXIS INC
(NASDAQ: STXS)

Stereotaxis, Inc designs, manufactures and markets robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. The Company offers its Epoch Solution, an advanced remote robotic navigation system for use in a hospital�s interventional surgical suite, or interventional lab. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System (Vdrive system). Its Niobe ES system is the latest generation of the Niobe Robotic Magnetic Navigation System (Niobe system), which allows physicians to more effectively navigate catheters, guidewires and other delivery devices, both its own and those the Company is co-developing through strategic alliances, through the blood vessels and chambers of the heart to treatment sites in order to effect treatment.

2.580 s

-0.060 (-2.27%)
Range 2.580 - 2.710   (5.04%)
Open 2.650
Previous Close 2.640
Bid Price 2.060
Bid Volume -
Ask Price 2.110
Ask Volume -
Volume 228,666
Value -
Remark s
Delayed prices. Updated at 18 Apr 2024 04:00.
Data powered by
View All Events

About STEREOTAXIS INC

Stereotaxis, Inc designs, manufactures and markets robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. The Company offers its Epoch Solution, an advanced remote robotic navigation system for use in a hospital�s interventional surgical suite, or interventional lab. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System (Vdrive system). Its Niobe ES system is the latest generation of the Niobe Robotic Magnetic Navigation System (Niobe system), which allows physicians to more effectively navigate catheters, guidewires and other delivery devices, both its own and those the Company is co-developing through strategic alliances, through the blood vessels and chambers of the heart to treatment sites in order to effect treatment.

Please login to view stock data and analysis